Pharmaceuticals – Page 2

Time is money in drug development – Healthcare Economist

June 3, 2024

0 Comments

Time is money in drug development – Healthcare Economist

Delays in drug approvals cost pharmaceutical firms money. These costs include both lost sales as well as additional cost if clinical trials need to ...

Recent Medicare attempts to lower drug prices (beyond IRA) – Healthcare Economist

May 29, 2024

0 Comments

Recent Medicare attempts to lower drug prices (beyond IRA) – Healthcare Economist

Recently, the Inflation Reduction Act (IRA) is getting a lot of attention, particularly for its provision that allows CMS to start drug price negotiation ...

May 13, 2024

0 Comments

Part 3 – Healthcare Economist

See my previous posts on IRA price negotiation on drug selection (Part 1) and manufacturer data submission (Part 2). Today we will talk about ...

May 9, 2024

0 Comments

Part 1 – Healthcare Economist

CMS released guidance on IRA price negotiation last week. Below are some highlights regarding how drugs will be selected. Which drugs are eligible for ...

EMA and delays in drug launch – Healthcare Economist

April 9, 2024

0 Comments

EMA and delays in drug launch – Healthcare Economist

For patients with serious illnesses, timeline access to efficacious medications is paramount. The European Medicines Agency (EMA) was created in part to help expedite ...

April 3, 2024

0 Comments

An overview – Healthcare Economist

A paper by Kogut (2024) has a nice overview of the organizations that develop pharmacy plan quality metrics. Pharmacy plan quality is vital since ...